Newly NASDAQ-listed China Nuokang Sees Revenue Growth Spurt
This article was originally published in PharmAsia News
HONG KONG - Underscoring the potential for growth for small biopharmaceutical companies, a Chinese developer and manufacturer of hematological and cardiovascular products reported higher earnings for 2009 and expects growth to carry into 2010
You may also be interested in...
China Nuokang Bio-Pharmaceutical, Dendreon, Afferent Pharmaceuticals, and Molecular Partners end the year with new funds.
HONG KONG - Concerns over valuation seem to be doing little to dampen enthusiasm for new Chinese pharmaceutical related stocks and the result is a minefield of opportunities on very shaky ground
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).